Prime Medicine Wins AATD Arbitration But Trails Beam by Years in Clinical Development

Prime Medicine Wins Gene Editing Dispute

Prime Medicine has successfully concluded a legal dispute with Beam Therapeutics concerning the development rights for gene editing therapies targeting alpha-1 antitrypsin deficiency (AATD). An arbitration panel ruled in Prime's favor on Wednesday, determining that Prime did not breach a 2019 collaboration agreement and therefore owes no monetary damages to Beam. This decision allows Prime to continue developing its "prime editing" AATD treatment, which is currently in preclinical testing with initial human data anticipated next year, while Beam's "base editing" treatment is in advanced clinical development.

• Legal Victory and Financial Impact: Prime Medicine secured a favorable ruling from an arbitration panel, confirming it did not breach its 2019 agreement with Beam Therapeutics. This outcome means Prime is not liable for any monetary damages to Beam, solidifying its position to independently advance its gene editing program for alpha-1 antitrypsin deficiency.
• Core of the Dispute and Technologies: The dispute centered on whether Prime's development of an AATD treatment violated a broad 2019 collaboration. The ruling clarifies Prime's rights to develop its "prime editing" therapy, distinct from Beam's "base editing" approach, both originating from David Liu's labs and targeting the same rare genetic condition.
• Development Pathway and Future Outlook: With the legal hurdle cleared, Prime Medicine can proceed with its "prime editing" AATD treatment, which is currently in preclinical testing. The company anticipates generating initial human data from this program next year, positioning it as a potential rival to Beam Therapeutics' "base editing" treatment, which is already in advanced clinical development.

Addressing Unmet Needs in Alpha-1 Antitrypsin Deficiency

Despite decades of clinical awareness, Alpha-1 antitrypsin deficiency remains substantially underdiagnosed and undertreated, with systemic gaps in testing, access, and therapeutic breadth continuing to limit patient outcomes. Recent literature highlights a clear shift toward expanding the clinical scope of AATD beyond its traditional association with emphysema in younger patients, alongside growing recognition of the disease's broader inflammatory and extrapulmonary dimensions.

• Diagnostic underrecognition and testing heterogeneity: Delayed diagnosis persists due to clinical overlap with asthma, COPD, and liver disease. Across European care pathways, 25% of physicians were unaware of local AATD testing guidelines, and approaches to sample testing and collection methods vary significantly between countries. A 2025 EMR-based reminder intervention increased testing rates only 3.8-fold (from 1.2% to 4.6%), underscoring the need for more robust, combined detection strategies such as enhanced awareness programmes paired with free testing and population-based screening.

• Limitations of current augmentation therapy: Intravenous augmentation therapy remains the mainstay of treatment but is expensive and variably reimbursed globally. Key clinical questions around dose optimisation, route of administration, and effects on exacerbation frequency, quality of life, lung function decline, and mortality remain unresolved, driving demand for next-generation therapeutic options.

• Expansion beyond the COPD phenotype: The traditional paradigm of a younger emphysematous AATD patient is increasingly recognised as insufficient. Emerging evidence supports association between AATD and asthma — with SERPINA1 Pi*S and Pi*Z variants linked to asthma risk and AAT mutations identified in 12.5% of Colombian adults with difficult-to-treat asthma — as well as bronchiectasis and other chronic inflammatory airway conditions. AAT is being actively investigated as a therapeutic agent across bronchiectasis, cystic fibrosis, and interstitial lung disease, including in non-deficiency states characterised by excessive inflammation and protease burden.

• Extrapulmonary and high-cost populations: Beyond pulmonary disease, extrapulmonary manifestations represent an emerging therapeutic frontier. Patients with concomitant liver disease carry substantially higher healthcare costs — all-cause costs per person-year range from US\$11,877 in the absence of organ involvement to US\$74,015 when both lung and liver disease are present, with liver transplant recipients incurring costs of US\$461,752 per person-year post-transplantation — highlighting this group as a priority for intervention.

• Need for phenotype-specific and personalised treatment strategies: A deeper evaluation of clinical, radiological, microbiological, and functional variables is needed to characterise distinct AATD phenotypes. Emerging translational research calls for personalised therapeutic regimens informed by individual patient profiles, positioning AAT as a common mechanistic lever for inflammatory disequilibrium across multiple disease contexts.

• Access and infrastructure gaps in specialist care: Twenty-eight percent of European respondents were unfamiliar with ERN-LUNG centres, with Portugal and Spain reporting the lowest familiarity, and cross-border utilisation of these specialist services remains limited. Uniform provision of therapeutic options and standardisation of care pathways across healthcare systems represents a critical and as-yet unmet structural need.

Emerging Gene Editing Mechanisms for AATD Treatment

Gene editing and gene therapy represent the most actively advancing frontier in AATD research, with multiple mechanistic platforms progressing from preclinical optimization to early clinical evaluation. These approaches aim to address the root genetic cause of AATD — pathogenic variants in SERPINA1 — rather than managing downstream protein deficiency or organ-level consequences.

• AAV-Mediated Gene Therapy for Durable AAT Expression: Adeno-associated virus (AAV)-based platforms — including AAV1 and AAV8 serotypes — are being optimized to achieve therapeutic serum AAT concentrations (≥11 µM) at clinically acceptable vector doses. Promoter strength and cassette architecture have emerged as the dominant determinants of AAV-AAT potency, with the chicken β-actin expression cassette consistently outperforming liver-specific promoter variants. Full-length, single-stranded vectors incorporating robust regulatory elements provide the highest transgene expression; self-complementary AAV vectors, by contrast, exhibit reduced overall expression attributable to required promoter truncation. A central challenge remains achieving therapeutic concentrations at vector doses below thresholds associated with severe adverse events.

• Transgene Engineering — Codon Optimization and Oxidation-Resistant Variants: Codon optimization of the SERPINA1 transgene has been evaluated as a potency-enhancement strategy but did not improve expression and in some cases modestly reduced AAT levels. An engineered oxidation-resistant AAT variant has also been assessed; while it yielded lower circulating protein levels, it may retain therapeutic potential through enhanced functional stability under oxidative conditions relevant to AATD lung pathology.

• Hepatocyte-Targeted Approaches to Correct Intracellular Polymerization: Mechanistic strategies targeting the liver focus on the intracellular retention and polymerization of Z-AAT within hepatocyte endoplasmic reticulum. Platforms under investigation include small interfering RNA (siRNA) to suppress production of misfolded Z-AAT polymer, small molecules designed to block intracellular polymerization, and modulation of proteostasis networks — including autophagy stimulation — to promote clearance of accumulated mutant protein.

• Induced Pluripotent Stem Cell (iPSC) Technology: Stem cell-based approaches are being explored as a strategy to correct the underlying SERPINA1 genetic defect, with iPSCs offering the potential to generate gene-corrected hepatocyte-like cells for autologous transplantation, though this remains in early investigational stages.

• Novel Recombinant AAT Isoforms and Functional Mimetics: Emerging research is expanding beyond classical SERPIN-based protease inhibition, recognizing that AAT also regulates inflammation, metabolism, and cell survival through mechanisms independent of anti-elastase activity. Novel recombinant isoforms and AAT-derived peptides that replicate these pleiotropic functions are under preclinical and early clinical investigation as potential alternatives or complements to plasma-derived augmentation therapy.

Key Clinical Trial Designs for AATD Gene Therapies

Clinical trials in AATD span a range of designs — from augmentation therapy evaluations to longitudinal biomarker studies — reflecting the field's evolving understanding of disease progression and therapeutic monitoring. The studies summarized below vary in scale and methodology but collectively define the key parameters, endpoints, and analytical frameworks used to evaluate interventions and outcomes in this rare disease.